We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Allergan plc | NYSE:AGN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
From May 2019 to May 2024
By Micah Maidenberg
Allergan PLC (AGN) reported stronger-than-expected revenue and a smaller loss for the fourth quarter.
The maker of Botox and other drugs on Monday reported $4.35 billion in revenue for the quarter, up about 7% from the year earlier and more than the $4.09 billion analysts polled by FactSet predicted.
Allergan said its loss attributable to shareholders narrowed to $317.2 million, or 97 cents a share, from $4.29 billion, or $12.83 a share, in the fourth quarter of 2018, when the company recorded impairments, affecting results.
Allergan's adjusted earnings for the latest period of $5.22 a share beat forecasts from analysts, who expected $4.57 a share on that metric.
AbbVie Inc. (ABBV) plans on combining with Allergan in a deal the companies believe will be completed in the first quarter.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
February 10, 2020 07:31 ET (12:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
